scholarly journals Re: Campochiaro et al.: The Port Delivery System with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 Ladder clinical trial (Ophthalmology. 2019;126:1141-1154)

Ophthalmology ◽  
2019 ◽  
Vol 126 (11) ◽  
pp. e87-e88 ◽  
Author(s):  
Ashish Sharma ◽  
Nilesh Kumar ◽  
Baruch D. Kuppermann ◽  
Bandello Francesco
Keyword(s):  
Clinical Trial ◽  
Macular Degeneration ◽  
Delivery System ◽  
Age Related Macular Degeneration ◽  
Phase 2 ◽  
Age Related ◽  
Randomized Phase 2

A Randomized Phase 2 Study of an Anti–Amyloid β Monoclonal Antibody in Geographic Atrophy Secondary to Age-Related Macular Degeneration

2018 ◽  
Vol 2 (10) ◽  
pp. 1028-1040 ◽  
Author(s):  
Philip J. Rosenfeld ◽  
Brian Berger ◽  
Elias Reichel ◽  
Ronald P. Danis ◽  
Angie Gress ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Macular Degeneration ◽  
Amyloid Β ◽  
Geographic Atrophy ◽  
Age Related Macular Degeneration ◽  
Phase 2 ◽  
Age Related ◽  
Phase 2 Study ◽  
Randomized Phase 2

scholarly journals Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration

2018 ◽  
Vol 34 (10) ◽  
pp. 700-709 ◽  
Author(s):  
David Callanan ◽  
Derek Kunimoto ◽  
Raj K. Maturi ◽  
Sunil S. Patel ◽  
Giovanni Staurenghi ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Phase 2 ◽  
Anti Vegf ◽  
Age Related ◽  
Randomized Phase 2
Sign in / Sign up

Export Citation Format

Share Document